Skip to main content

Table 1 clinical characteristics in MetS and non-MetS patients with poor and good collateralization

From: Metabolic syndrome and its components reduce coronary collateralization in chronic total occlusion: An observational study

Variables

Overall

MetS

non-MetS

Poor collateralization n = 355

Good collateralization n = 1298

P value

Poor collateralization n = 222

Good collateralization n = 640

P value

Poor collateralization n = 133

Good collateralization n = 658

P value

Male, n(%)

294 (82.8)

1074 (82.7)

0.974

174 (78.4)

508 (79.4)

0.753

120 (90.2)

566 (86.0)

0.192

Age, years

57.7 ± 10.5

59.1 ± 10.3

0.022

57.2 ± 10.6

58.7 ± 10.2

0.057

58.6 ± 10.4

59.6 ± 10.3

0.346

BMI, Kg/m2

28.1 ± 3.7

26.0 ± 3.1

 < 0.001

28.9 ± 4.0

26.9 ± 3.1

 < 0.001

26.9 ± 2.8

25.2 ± 2.8

 < 0.001

HT, n(%)

255 (71.8)

816 (62.9)

0.002

182 (82.0)

497 (77.7)

0.174

73 (54.9)

319 (48.5)

0.178

T2DM, n(%)

156 (43.9)

414 (31.9)

 < 0.001

118 (53.2)

285 (44.5)

0.027

38 (28.6)

129 (19.6)

0.021

Renal disease, n(%)

10 (2.8)

25 (1.9)

0.302

8 (3.6)

13 (2.0)

0.190

2 (1.5)

12 (1.8)

0.799

Metabolic syndrome, n(%)

222 (62.5)

640 (49.3)

 < 0.001

–

–

–

–

–

–

Former smoker, n(%)

56 (15.8)

211 (16.3)

0.827

32 (14.4)

98 (15.3)

0.747

24 (18.0)

113 (17.2)

0.809

Current smoker, n(%)

146 (41.1)

540 (41.6)

0.872

80 (36.0)

267 (41.7)

0.137

66 (49.6)

273 (41.5)

0.197

Prior MI, n(%)

102 (28.7)

359 (27.7)

0.689

63 (28.4)

189 (29.5)

0.745

39 (29.3)

170 (25.8)

0.405

Stroke, n(%)

20 (5.6)

89 (6.9)

0.411

14 (6.3)

49 (7.7)

0.505

6 (4.5)

40 (6.1)

0.481

History of PCI, n(%)

103 (29.0)

386 (29.7)

0.791

69 (31.1)

211 (33.0)

0.605

34 (25.6)

175 (26.6)

0.806

SBP, mmHg

132.6 ± 16.1

127.3 ± 16.1

 < 0.001

135.1 ± 15.5

128.6 ± 16.3

 < 0.001

128.3 ± 16.4

126.0 ± 15.7

0.117

DBP, mmHg

79.5 ± 11.8

75.7 ± 10.6

 < 0.001

81.0 ± 12.0

76.3 ± 10.6

 < 0.001

77.2 ± 11.0

75.0 ± 10.5

0.033

HR, bpm

71.7 ± 9.4

72.0 ± 10.5

0.558

71.8 ± 9.4

72.7 ± 10.5

0.309

71.4 ± 9.3

71.4 ± 10.5

0.967

FBG, mmol/L

6.2 (5.1, 8.1)

5.7 (5.1, 7.2)

 < 0.001

6.9 (5.6, 8.1)

6.4 (5.5, 8.1)

0.033

5.4 (4.9, 6.4)

5.3 (4.9, 5.9)

0.163

TG, mmol/L

1.6 (1.2,2.4)

1.4 (1.0,2.0)

 < 0.001

2.0 (1.6, 2.8)

1.9 (1.3, 2.5)

0.002

1.2 (1.1, 1.6)

1.1 (0.9, 1.4)

 < 0.001

TC, mmol/L

4.1 ± 1.3

3.8 ± 1.0

0.001

4.1 ± 1.5

3.8 ± 1.1

0.004

4.0 ± 1.0

3.8 ± 1.0

0.109

LDL-C, mmol/L

2.3 ± 1.0

2.2 ± 0.9

0.189

2.3 ± 1.1

2.2 ± 0.9

0.319

2.4 ± 0.9

2.3 ± 0.9

0.257

HDL-C, mmol/L

1.0 (0.8, 1.2)

1.0 (0.9, 1.2)

0.007

0.9 (0.8, 1.0)

0.9(0.8, 1.0)

0.545

1.1(0.9, 1.2)

1.1(1.0, 1.3)

0.489

WBC, 1012/L

7.1 ± 1.8

7.0 ± 1.8

0.179

7.0 ± 1.8

7.1 ± 1.8

0.526

7.2 ± 1.8

6.8 ± 1.8

0.052

HGB, g/L

144 (133,153)

142 (132,152)

0.149

143 (133, 154)

142 (132, 152)

0.293

144 (134,152)

142 (132, 152)

0.345

PLT, 109/L

217.2 ± 54.5

218.4 ± 57.0

0.719

219.0 ± 54.8

219.4 ± 57.0

0.803

214.1 ± 54.1

217.4 ± 57.1

0.546

Cr, μmol/L

78.5 ± 21.5

77.0 ± 33.1

0.418

79.3 ± 23.7

77.9 ± 31.4

0.562

77.3 ± 17.2

76.1 ± 34.6

0.712

UA, μmol/L

361.2 (310.9, 418.2)

350.7 (299.2, 419.0)

0.186

364.1 (311.0, 425.3)

363.6 (307.5, 432.7)

0.778

357.5 (309.2, 410.9)

341.1 (291.3, 406.1)

0.072

eGFR, mL/(min·1.73 m2)

92.8 ± 17.5

93.3 ± 17.0

0.657

92.0 ± 18.9

92.6 ± 17.8

0.676

94.3 ± 14.8

94.0 ± 16.1

0.834

HCY, μmol/L

16.2 ± 8.9

16.2 ± 10.0

0.930

15.7 ± 8.1

15.8 ± 9.6

0.878

17.0 ± 10.1

16.6 ± 10.3

0.715

GA, %

15.3 (13.8, 17.8)

14.5 (13.3, 16.6)

 < 0.001

15.6 (14.0, 18.0)

14.9 (13.4,18.3)

0.023

14.7 (13.5, 16.7)

14.2 (13.3, 15.8)

0.039

LVEF, %

56.9 ± 7.8

56.1 ± 7.8

0.134

57.0 ± 7.2

56.6 ± 7.7

0.513

56.8 ± 8.6

55.8 ± 7.9

0.212

LVEDd, mm

50.6 ± 5.2

51.0 ± 5.2

0.249

50.1 ± 5.0

50.8 ± 5.2

0.084

51.5 ± 5.5

51.2 ± 5.2

0.502

LVEDs, mm

35.3 ± 6.0

35.8 ± 5.8

0.164

35.0 ± 5.4

35.5 ± 5.7

0.254

35.8 ± 6.8

36.1 ± 5.8

0.644

Medication, n (%)

Antiplatelet

355 (100)

1298 (100)

1

222 (100)

640 (100)

1

133 (100)

658 (100)

1

Statins

355 (100)

1298 (100)

1

222 (100)

640 (100)

1

133 (100)

658 (100)

1

Diuretics

45 (12.4)

158 (12.2)

0.798

33 (14.9)

84 (13.1)

0.514

12 (9.0)

74 (11.2)

0.452

ACE inhibitors/ARBs

150 (42.3)

471 (36.3)

0.040

107 (48.2)

276 (43.1)

0.190

43 (32.3)

195 (29.6)

0.536

β-blockers

236 (66.5)

846 (65.2)

0.648

148 (66.7)

446 (69.7)

0.402

88 (66.2)

400 (60.8)

0.245

CCBs

111 (31.3)

369 (28.4)

0.296

71 (31.3)

221 (34.6)

0.489

40 (30.1)

148 (22.5)

0.061

Hypoglycaemic agents

107 (30.1)

320 (24.7)

0.036

83 (37.4)

216 (33.8)

0.327

24 (18.0)

104 (15.3)

0.522

Target vessel, n (%)

RCA

167 (47.0)

576 (44.4)

0.371

104 (46.8)

288 (45.0)

0.634

63 (47.4)

288 (43.8)

0.446

LAD

132 (37.2)

491 (37.8)

0.824

89 (40.1)

227 (35.5)

0.218

43 (32.3)

264 (40.1)

0.093

LCX

63 (17.7)

240 (18.5)

0.748

33 (14.9)

130 (20.3)

0.074

30 (22.6)

110 (16.7)

0.109

Elevated BMI, n (%)

88 (24.8)

136 (10.5)

 < 0.001

83 (37.4)

117 (18.3)

 < 0.001

5 (3.8)

19 (2.9)

0.593

Elevated BP,n (%)

293 (82.5)

957 (73.7)

0.001

208 (97.3)

559 (87.3)

0.009

85 (63.9)

398 (60.5)

0.460

Elevated FBG, n (%)

238 (67.0)

751 (57.9)

0.002

181 (81.5)

516 (80.6)

0.767

57 (42.9)

235 (35.7)

0.119

Reduced HDL-C, n (%)

247 (69.6)

837 (64.5)

0.073

195 (87.8)

580 (90.6)

0.235

52 (39.1)

257 (39.1)

0.993

Elevated TG, n (%)

166 (46.8)

447 (34.4)

 < 0.001

147 (66.2)

376 (58.8)

0.050

19 (14.3)

71

(10.8)

0.247

  1. BMI body mass index, HT Hypertension, T2DM type 2 diabetes mellitus, Prior MI Prior myocardial infarction, History of PCI history of percutaneous coronary intervention, History of CABG history of coronary artery bypass grafting, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, FBG Fasting blood glucose, TG Triglycerides, TC Total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, WBC white blood cell, HGB hemoglobin, PLT Platelet, Cr creatinine, UA Uric acid, HCY Homocysteine, GA Glycated albumin, LVEF ventricular ejection fraction, LVEDd left ventricular end-diastolic dimension, LVEDsleft ventricular end-systolic dimension, ACE inhibitors/ARBs Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers, CCBs calcium channel blockers, RCA Right coronary artery, LAD Left anterior descending, LCX left circumflex coronary artery